Key Stats for Biogen Inc. Stock
- Current Price: $181
- Target Price: $189
- Street Target: $206
- Potential Total Return: 4.21%
- Annualized IRR: 0.9%
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free) >>>
What Happened?
Biogen Inc. (BIIB) is currently navigating a high-stakes transition from its legacy Multiple Sclerosis (MS) franchise toward a speculative, multi-pronged pipeline focused on “next-generation” CNS and immunology targets.
Speaking at the Stifel CNS Forum in March 2026, Biogen leadership detailed the “CELIA” proof-of-concept study for BIIB080, an antisense oligonucleotide (ASO) targeting the tau protein.
Unlike traditional amyloid-clearing drugs, tau pathology, often visualized as “tangles” in the brain, is believed to spread in a way that coincides much more closely with actual cognitive decline than amyloid burden.
Beyond Alzheimer’s, the company is advancing salanersen, an investigational SMA therapy designed for once-yearly dosing.
This would represent a major logistical leap over Biogen’s legacy SPINRAZA, which requires more frequent administration.
Early data have demonstrated that salanersen can rapidly reduce neurofilament levels, a primary biomarker of active neurodegeneration, even in patients who showed suboptimal responses to previous gene therapies.
See historical and forward estimates for Biogen Inc. stock (It’s free!) >>>
In the immunology sector, Biogen recently produced a positive Phase III SLE result for Dapirolizumab pegol (DAPI).
Management emphasized that DAPI was specifically engineered without an “Fc fragment” to prevent the platelet-clotting and thrombosis risks that have historically derailed therapies in this class.
Diana Gallagher, Head of Clinical Development, summarized the strategy: “The emergence of tau pathology really coincides even more closely than amyloid prevalence with the coincident cognitive decline… we believe that the best way to fully test the hypothesis [is] to really shut down all the isoforms and see what happens.”
Is Biogen Inc. Undervalued Today?
The market’s current valuation of Biogen reflects deep skepticism regarding the company’s ability to replace its eroding legacy MS revenue.
The successful rollout of LEQEMBI and potential approvals for salanersen are currently only enough to keep the top line flat.
The target price of $189.09 sits significantly below the $205.90 Street Target, representing a defensive 4.21% total return projection over the next five years.
This conservative outlook is driven by “logistical friction” in the pipeline; for instance, the CELIA trial for BIIB080 requires intrathecal (spinal) administration every 3 to 6 months.
While Biogen is developing a non-IT “backup” tau candidate, that asset remains in the preclinical phase and cannot contribute to near-term earnings.
Furthermore, the competitive landscape is intensifying. While Biogen and Eisai lead the AHEAD 3-45 study in presymptomatic patients with low plaque levels (20–40 centiloids), they are racing against Eli Lilly’s (LLY) donanemab (the TRAILBLAZER-ALZ 3 study).
See whether Biogen Inc. is undervalued vs peers (It’s free!) >>>
TIKR Advanced Model Analysis
The TIKR Advanced Model illustrates a biotech giant in a state of clinical flux, where margins remain robust, but top-line growth is nonexistent.
- Current Price: $181
- Target Price: $189
- Potential Total Return: 4.2%
- Annualized IRR: 0.9%
Build a 4-year Valuation Model for Biogen Inc. for yourself (It’s free) >>>
A high-margin but stagnant growth profile anchors the Mid Case projections for the $189.09 target. The model forecasts a 27.1% Net Income Margin, showing that Biogen remains an efficient cash-flow generator even as revenue growth stalls at a (0.4%) CAGR.
The primary “lever” for investors is the CELIA trial readout. If the ASO approach can prove clinical efficacy in tau knockdown, it would validate a multi-billion-dollar platform. However, until that clinical proof is realized, Biogen represents a defensive play. The stock is currently priced for clinical survival rather than immediate expansion, securing a modest 0.9% annualized return as it bridges the gap between its legacy portfolio and its 2028 pipeline readouts.
Conclusion: Biogen Inc. is a study in scientific ambition versus financial gravity. By leading the charge in tau knockdown, neuromuscular potency, and lupus immunology, the company is building the infrastructure for the next generation of medicine. However, for long-term investors, the projected $189.09 valuation underscores that scientific success in the lab has yet to translate into a growth engine for the stock.
See what stocks billionaire investors are buying so you can follow the smart money with TIKR.
Should You Invest in Biogen Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up Biogen Inc., and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Biogen Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Analyze Biogen Inc. on TIKR Free →
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
